Discovery of AZD3199, An Inhaled Ultra long Acting β2 Receptor Agonist with Rapid Onset of Action

A series of dibasic des-hydroxy beta(2) receptor agonists has been prepared and evaluated for potential as inhaled ultralong acting bronchodilators. Determination of activities at the human beta-adrenoreceptors demonstrated a series of highly potent and selective beta(2) receptor agonists that were progressed to further study in a guinea pig histamine-induced bronchoconstriction model. Following further assessment by onset studies in guinea pig tracheal rings and human bronchial rings contracted with methacholine (guinea pigs) or carbachol (humans), duration of action studies in guinea pigs after intratracheal (i.t.) administration and further selectivity and safety profiling AZD3199 was shown to have an excellent over all profile and was progressed into clinical evaluation as a new ultralong acting inhaled beta(2) receptor agonist with rapid onset of action.